Trials / Completed
CompletedNCT04971590
Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis
LUNELORD: A Descriptive, Prospective Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and QoL of Patients With LUpus NEphritis and Long-term ORgan Damage
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 193 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter prospective study to assess clinical characteristics, demographics, treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants across 5 Gulf countries (United Arab Emirates \[UAE\], Qatar, Bahrain, Kuwait and Oman).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Participant completed survey | Participants will be required to complete the participant survey. |
| OTHER | Medical chart review | Data will be collected from medical charts of participants. |
Timeline
- Start date
- 2021-09-14
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
- First posted
- 2021-07-21
- Last updated
- 2026-01-22
- Results posted
- 2026-01-22
Locations
6 sites across 4 countries: Kuwait, Oman, Qatar, United Arab Emirates
Source: ClinicalTrials.gov record NCT04971590. Inclusion in this directory is not an endorsement.